4:00 PM
 | 
Sep 13, 2017
 |  BC Extra  |  Company News

FDA panel backs GSK’s shingles vaccine

FDA’s Vaccines and Related Biological Products Advisory Committee voted 11-0 that available data support the safety and efficacy of Shingrix herpes zoster vaccine from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to prevent shingles in adults ages 50 and older. GSK, which submitted the application last...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >